12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Adasuve Staccato loxapine regulatory update

FDA issued a complete response letter for an NDA from Alexza for inhaled Adasuve Staccato loxapine to treat agitation in patients with schizophrenia or bipolar disorder. According to Alexza, FDA said it identified manufacturing deficiencies at the company's Mountain View, Calif., plant during a recent inspection. Alexza said it believes the deficiencies are...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >